2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 46

Organic Dust Inhalants Shift Immune Responses and Extracellular Matrix Balance between Synovium and Lung in the Collagen-Induced Arthritis Mouse Model
Abstract Number: 1239

Organisms Associated with Prosthetic Joint Septic Arthritis over the Past Two Decades: Data from a Single Tertiary Medical Center Located in the Northeastern United States
Abstract Number: 1904

Orphan Nuclear Receptor Rorα Is a Key Regulator of Tgfβ- and WNT-Signaling in Fibrotic Diseases
Abstract Number: 1994

Osteoarthritis Severity Is Reduced By Intra-Articular Administration of Hydrogen Sulfide
Abstract Number: 1824

Osteoclast Derived-Autotaxin, a Distinguishing Factor for Inflammatory Bone Loss
Abstract Number: 2335

Osteoporotic Fracture Trends in a Population of US Managed Care Enrollees: 2007-2017
Abstract Number: 260

Outcome Expectations and Fibromyalgia: Perceived Benefits of Exercise Are Associated with Self-Efficacy and Physical Performance
Abstract Number: 743

Outcome of Stroke in Patients with Systemic Lupus Erythematosus: A Nested Case-Control Study
Abstract Number: 239

Outcomes of Hospitalizations and the Temporal Trends in Mortality from Acute Myocardial Infarction in Patients with RA and FM during 2005 to 2015
Abstract Number: 2440

Outcomes of Pregnancy Complicated By ANCA-Associated Vasculitis: A Retrospective Review
Abstract Number: 277

Outcomes of Telemedicine for Rheumatoid Arthritis in the Alaska Native Population
Abstract Number: 2326

Outcomes One Year after Hip Fracture Repair in the Elderly: Does Social Isolation Matter?
Abstract Number: 2172

Overuse of Glucocorticoids in Rheumatoid Arthritis: A National Survey of Primary Care Physicians
Abstract Number: 11

PAD4-Independent Interaction of ACPA with Nuclear Antigens in Apoptotic Cells and Neutrophil Extracellular Traps (NETs) Defines a Subset of Autoantibodies
Abstract Number: 1523

Pain Is Improved in Around 50% of Patients and Fatigue in 40% of Patients with Rheumatoid Arthritis Treated with Sarilumab in the Target, Mobility and Monarch Trials

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].